ClinicalTrials.gg
CompletedNCT05008419Updated Oct 7, 2026

Narrative Discourse Treatment Development

An interventional study of Narrative discourse treatment in Traumatic Brain Injury and Neurogenic Communication Disorders, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Brain Injuries, Traumatic · VA Office of Research and Development.

Enrollment
30th of 46
34 · median 61
Started
2023
with 1 other
No phase
37 of 55
4 open now
Registered
45th of 55
by date

Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, this one is the 30th largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2023, is one of 37 with no phase, and was the 45th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

8 of the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

Discourse impairments are breakdowns in meaningful communication beyond the level of single sentences and have a functional impact on the lives of Veterans with traumatic brain injury (TBI), disrupting return to work, communication re integration, socialization, and quality of life. The few prior attempts to treat discourse impairments have been small case studies and resulted in no change or limited gains. The proposed study evaluates the feasibility of a novel narrative discourse treatment that builds upon these prior attempts by addressing breakdowns in both story content and story organization using a theoretically-driven approach. If feasible, as demonstrated by tolerability and acceptability to participants, and later shown to be effective, the proposed discourse treatment has the potential to improve daily communication, which provides a gateway for Veterans with TBI to increase meaningful participation and improve functioning in major life domains.

Read the detailed description

Discourse intervention in TBI is a nascent area of research, and, to date, there have been only a few studies that have attempted to improve discourse ability in TBI. These prior attempts have been small case studies, produced no change or limited gains, and did not include Veterans with TBI. The proposed project is an early stage discourse treatment development study that will evaluate the feasibility of a novel narrative discourse treatment protocol that builds upon these prior attempts with an all-Veteran participant sample. The first part of the study will consist of initial manual development for the discourse treatment protocol and refinement.

The second part will involve a treatment feasibility trial to obtain information regarding the tolerability, acceptability, and fidelity of the proposed discourse treatment and preliminary data on treatment delivery and assessment methods as well as preliminary information about treatment effects. Forty participants will be randomized to either the discourse treatment group or Treatment as Usual control. Assessments will be conducted at baseline, post-treatment, and at 1-month follow-up.

03

Conditions studied

  • Traumatic Brain Injury
  • Neurogenic Communication Disorders

Keywords

  • traumatic brain injury
  • neurogenic communication disorders
  • pragmatic communication disorders
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veteran with diagnosis of traumatic brain injury (TBI) with mild to moderate functional cognitive impairments
  • Self-report of communication difficulty following traumatic brain injury that interferes with activities
  • Can identify a significant other (e.g., spouse, family member, friend) who is able and willing to serve as an informant, who will verify discourse ability pre- and post-treatment

    • The informant must be an individual with whom the participant engages in weekly social communication
  • Adequate hearing and visual acuity to participate in study procedures
  • Those who are willing and able to participate in telehealth sessions must have appropriate equipment and access

    • e.g., smartphone, tablet, computer with camera, internet access
  • Stable housing

    • Participants must have a safe, private and quiet environment in their home to engage in telehealth sessions
  • English as a primary language

Exclusion criteria

Exclusion Criteria:

  • Penetrating head injury
  • History of or current developmental disability (e.g., dyslexia), psychotic disorder, neurological illness

    • e.g., stroke, dementia, Parkinson's disease), aphasia or auditory processing disorder (APD)
  • Current (past 30 days) diagnosis of alcohol or substance abuse

    • An exception will be made for marijuana as a number of Veterans use marijuana occasionally to manage ailments, such as pain and post-traumatic stress disorder (PTSD)
    • Marijuana use must not occur regularly or interfere with daily functioning
    • Inclusion of Veterans using marijuana aligns with the VA's position that Veterans will not be denied VA benefits because of marijuana use
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Discourse Treatment

    Biweekly discourse treatment sessions.

    Behavioral: Narrative discourse treatment

  • No intervention
    Treatment as Usual

    No treatment. Participants will engage in their usual care.

Interventions

  • BehavioralNarrative discourse treatment

    The protocol will incorporate elements from prior treatment studies that showed some promise: 1) hierarchical training, 2) variety of discourse stimuli, 3) development of skills and strategies for discourse processing, 4) structured training prompts, 5) meta-cognitive and meta-linguistic strategies, and 6) integration of learning principles. Novel treatment elements will include: 1) targeting both story content and story organization, 2) use of a discourse model to guide treatment, and 3) functional communication training. Treatment will be delivered twice a week over 8 weeks. There will be four treatment phases: education, story organization, story content, and integration of story organization and content.

06

What researchers measure

Primary outcomes

  1. Tolerability of treatment as measured by rates of attendance for all aspects of treatment

    Rates of attendance for all aspects of treatment, calculated as the number of treatment sessions attended across all treatment phases divided by total number of treatment sessions.

    Time frame: 2 months

  2. Feasibility of treatment as measured by dropout rate in the treatment condition

    Dropout rate in the treatment condition will be calculated as the number of participants who do not complete treatment over total number of participants

    Time frame: 2 months

  3. Acceptability of treatment as measured by a treatment satisfaction survey

    Percentage of participants who rate satisfaction with the treatment based on Likert-type survey (e.g., endorse "satisfied" or "very satisfied")

    Time frame: 2 months

07

Study locations

1 site
  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT
    West Haven, Connecticut 06516-2770, United States
08

References and documents

Publications

  • Le K, Coelho C, Feinn R, Fiszdon JM. Talking About Life Experiences: Protocol for Treatment Development and a Feasibility Trial of a Novel Narrative Discourse Intervention for Individuals With Traumatic Brain Injury. JMIR Res Protoc. 2026 Apr 24;15:e86329. doi: 10.2196/86329. PubMed 42061839 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Final data sets underlying all publications resulting from the research may be shared as per access criteria delineated below.

Time frame: 6 months after publication

Access criteria: De-identified data sets may be shared with other investigators, upon written request, under a data use agreement prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset. The data sharing agreement will also restrict redistribution to third parties and proper acknowledgment of the data source. These data sets will be shared per guidelines provided by the VA Connecticut Healthcare System (VACHS) Information Security Officer.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Oct 2025, 22 months.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's 22 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Sep 2026 → Oct 2025 and completion Sep 2026 → Oct 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2021
First posted
Aug 17, 2021
StartActual
Nov 27, 2023
Primary completionActual
Oct 10, 2025was Sep 2026
CompletionActual
Oct 10, 2025was Sep 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Primary completion
Sep 30, 2026→Oct 10, 2025 (actual)
Oct 7, 2026
Study completion
Sep 30, 2026→Oct 10, 2025 (actual)
Oct 7, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedVeteran with diagnosis of traumatic brain injury (TBI) with mild to moderate functional cognitive impairments
  • EditedSelf-report of communication difficulty following TBItraumatic brain injury that interferes with activities
Exclusion criteria
  • EditedAn exception will be made for marijuana as a number of Veterans use marijuana occasionally to manage ailments, such as pain and post-traumatic stress disorder (PTSD)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    Primary completion Sep 30, 2026→Oct 10, 2025 (now actual)
    Study completion Sep 30, 2026→Oct 10, 2025 (now actual)
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedVeteran with diagnosis of traumatic brain injury (TBI) with mild to moderate functional cognitive impairments
    • EditedSelf-report of communication difficulty following TBItraumatic brain injury that interferes with activities
    Exclusion criteria
    • EditedAn exception will be made for marijuana as a number of Veterans use marijuana occasionally to manage ailments, such as pain and post-traumatic stress disorder (PTSD)
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05008419
Responsible party
Sponsor
First posted
Aug 17, 2021
Start date
Nov 27, 2023
Primary completion
Oct 10, 2025
Completion
Oct 10, 2025
Last update
Oct 7, 2026

Study contacts

Karen Le, PhD
principal investigator · VA Connecticut Healthcare System West Haven Campus, West Haven, CT

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion